MAO inhibitors
DXM combinations with substances in this group.
PHI is a provisional hazard rating for a combination with DXM on a 0–10 scale.
- No PHI rating
Why is there no PHI rating?
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
Find combinations by mechanism
Here the combinations are grouped by interaction mechanism.
Serotonin-related (7)
- DXM + Harmine, harmaline, Syrian rue, ayahuasca, harmala-containing changaPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Other reversible MAO-A inhibitorsPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Phenelzine, tranylcypromine, isocarboxazidPHI 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
- DXM + Selegiline or rasagiline, when MAO-B selectivity is lostPHI 8 to 9
Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
Cardiovascular and thermal
This category is not marked in the review
Sedation and respiration
This category is not marked in the review
Metabolism (1)
NMDA
This category is not marked in the review
Antimuscarinic
This category is not marked in the review
Seizure-related concern
This category is not marked in the review
Other discussed pathways
This category is not marked in the review